CONSOLIDATED STATEMENTS OF INCOME (LOSS) (USD $) In Millions, except Per Share data, unless otherwise specified	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Revenues
Product sales	$ 8,103.6	$ 5,640.3	$ 3,288.6
Other revenues	159.9	129.3	191.8
Total revenues	8,263.5	5,769.6	3,480.4
Expenses
Cost of goods sold (exclusive of amortization and impairments of finite-lived intangible assets shown separately below)	2,196.2	1,846.3	905.1
Cost of other revenues	58.4	58.8	64.6
Selling, general and administrative	2,026.3	1,305.2	756.1
Research and development	246.0	156.8	79.1
Amortization and impairments of finite-lived intangible assets (see Note 10)	1,550.7	1,902.0	928.9
Restructuring, integration and other costs	381.7	462.0	267.1
In-process research and development impairments and other charges	41.0	153.6	189.9
Acquisition-related costs	6.3	36.4	78.6
Acquisition-related contingent consideration	(14.1)	(29.2)	(5.3)
Other (income) expense (see Notes 3, 4, and 20)	(268.7)	287.2	136.6
Total expenses	6,223.8	6,179.1	3,400.7
Operating income (loss)	2,039.7	(409.5)	79.7
Interest income	5.0	8.0	6.0
Interest expense	(971.0)	(844.3)	(481.6)
Loss on extinguishment of debt	(129.6)	(65.0)	(20.1)
Foreign exchange and other	(144.1)	(9.4)	19.7
Gain on investments, net (see Note 23)	292.6	5.8	2.1
Income (loss) before provision for (recovery of) income taxes	1,092.6	(1,314.4)	(394.2)
Provision for (recovery of) income taxes	180.4	(450.8)	(278.2)
Net income (loss)	912.2	(863.6)	(116.0)
Less: Net (loss) income attributable to noncontrolling interest	(1.3)	2.5	0
Net income (loss) attributable to Valeant Pharmaceuticals International, Inc.	$ 913.5	$ (866.1)	$ (116.0)
Earnings (loss) per share attributable to Valeant Pharmaceuticals International, Inc.:
Basic (in dollars per share)	$ 2.72	$ (2.70)	$ (0.38)
Diluted (in dollars per share)	$ 2.67	$ (2.70)	$ (0.38)
Weighted-average common shares (in millions)
Basic (in shares)	335.4	321.0	305.4
Diluted (in shares)	341.5	321.0	305.4